Raymond James Financial Services Advisors’s Dermata Therapeutics DRMA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-59	Closed	-$58K	–	3297
2022 Q4	$58K	Buy	+59	New	+$74K	﹤0.01%	3070

Other funds holding DRMA

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Raymond James Financial Services Advisors's DRMA Position: Q1 2023 in Review

Raymond James Financial Services Advisors sold out of Dermata Therapeutics (DRMA) in Q1 2023, closing a stake of 59 shares — an estimated $58K sold.

Raymond James Financial Services Advisors first reported a position in DRMA in Q4 2022 and held it in 1 quarter. The position peaked at $58K in Q4 2022. 4 funds tracked by Wall St. Rank hold DRMA as of Q1 2023.

Raymond James Financial Services Advisors reported no remaining Dermata Therapeutics position as of Q1 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 59 Dermata Therapeutics shares in Q1 2023, an estimated $58K.
Raymond James Financial Services Advisors first reported a position in Dermata Therapeutics in Q4 2022 and held it in 1 quarter.
Raymond James Financial Services Advisors's Dermata Therapeutics position peaked at $58K in Q4 2022.
4 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2023, filed 14 Apr 2023.